Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amogammadex Sodium for Reversal of Neuromuscular Blockade
NCT07595393Phase 2Not yet recruiting
- Sponsor
- Amckaus PTY LTD
- Start
- Aug 2026
- Primary completion
- Jun 2027
01
Overview
Phase 2, open-label trial in neuromuscular blockade (NMB) (8 arms), sponsored by Amckaus PTY LTD. Primary endpoint: Time from the start of the administration of amogammadex sodium to the recovery of the TOFr to 0.9 at day 1. Planned start Aug 2026; status: not yet recruiting.
02
Conditions
neuromuscular blockade (NMB)
Beyond the preview
Go deeper on NCT07595393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07595393.